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Mutations in the DNA methyltransferase 3A (DNMT3A) gene are
the most common cause of age-related clonal hematopoiesis
(ARCH) in older individuals, and are among the most common
initiating events for acute myeloid leukemia (AML). The most fre-
quent DNMT3A mutation in AML patients (R882H) encodes a
dominant-negative protein that reduces methyltransferase activ-
ity by ∼80% in cells with heterozygous mutations, causing a focal,
canonical DNA hypomethylation phenotype; this phenotype is par-
tially recapitulated in murine Dnmt3a−/− bone marrow cells. To de-
termine whether the hypomethylation phenotype of Dnmt3a−/−
hematopoietic cells is reversible, we developed an inducible trans-
gene to restore expression of DNMT3A in transplanted bone marrow
cells from Dnmt3a−/− mice. Partial remethylation was detected
within 1 wk, but near-complete remethylation required 6 mo. Reme-
thylation was accurate, dynamic, and highly ordered, suggesting that
differentially methylated regions have unique properties that may be
relevant for their functions. Importantly, 22 wk of DNMT3A addback
partially corrected dysregulated gene expression, and mitigated the
expansion of myeloid cells. These data show that restoring DNMT3A
expression can alter the epigenetic “state” created by loss of Dnmt3a
activity; this genetic proof-of-concept experiment suggests that this
approach could be relevant for patients with ARCH or AML caused by
loss-of-function DNMT3A mutations.
DNA methylation | DNA methyltransferase | hematopoiesis |
gene expression
Mutations in the DNMT3A gene are the most common eventsassociated with age-related clonal hematopoiesis (ARCH)
(1–4), and are among the most common initiating mutations in acute
myeloid leukemia (AML) (5–7). In patients with AML, heterozygous
point mutations that cause missense changes at amino acid R882
(R882H, R882C, R882S, etc.) are by far the most prevalent (5, 8–12).
The R882 residue is near the distal dimerization site of the DNA
methyltransferase domain; the mutant R882H protein interacts
preferentially with wild-type (WT) DNMT3A, which creates a
“sink” that traps the WT protein in inactive heterodimers. Since
active isoforms of DNMT3B are generally not expressed in AML
cells, the de novo methylation capacity of cells with heterozygous
DNMT3AR882H mutations is reduced by ∼80%, resulting in thousands
of focal differentially methylated regions (DMRs) that occur in the
same position in every patient tested (i.e., they are “canonical” in lo-
cation), and nearly all of which are hypomethylated (13, 14). Although
many of these DMRs are located within or near genes, very few closely
linked genes have been found to be differentially expressed (13, 14).
In AML cells that are WT for DNMT3A, a large number of CpG
islands (CGI) are hypermethylated (14), a finding that is common to
many cancer types; however, this phenotype is mitigated in R882
mutant AMLs, suggesting that CGI hypermethylation is, in fact,
caused by DNMT3A activity. The genomes of DNMT3AR882 mutant
AML samples also have many hypomethylated DMRs that are not
associated with CGI, suggesting that there are additional regions in
hematopoietic cell genomes where DNA methylation is DNMT3A-
dependent (13–18). Likewise, a child with Tatton-Brown-Rahman
syndrome caused by an inherited DNMT3AR882H mutation was
found to have a focal hypomethylation phenotype in his nonleukemic
hematopoietic cells (14), suggesting that this epigenetic state exists
before transformation, and may therefore be relevant for the initia-
tion of myeloid malignancies (14, 19–22).
Significance
Mutations that reduce the function of the de novo DNA
methyltransferase, DNMT3A, are very common in patients with
clonal hematopoiesis and hematopoietic malignancies. Re-
storing the function of DNMT3A in mouse hematopoietic cells
deficient for this protein corrects the DNA methylation defect
in an ordered fashion, and partially restores abnormalities in
gene expression and myeloid population skewing. These data
may be relevant for therapeutic strategies designed to restore
DNMT3A activity in patients with diseases caused by mutations
in this gene.
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Murine hematopoietic cells that are constitutively deficient for
Dnmt3a have thousands of DMRs that possess a focal, canonical
hypomethylation phenotype (13, 16). Dnmt3a deficiency is as-
sociated with expansion and immortalization of hematopoietic
stem cells, a block in hematopoietic differentiation, and the
development of myeloid and lymphoid malignancies after a long
latent period (17, 23, 24). Young mice with Dnmt3a deficiency
have essentially normal blood counts and hematopoietic devel-
opment, despite the hypomethylation phenotype. While humans
with complete DNMT3A deficiency in their bone marrow cells
have not been described, many patients with ARCH—and some
with AML—have heterozygous loss-of-function mutations in
DNMT3A that cause haploinsufficiency (16). In mice, Dnmt3a
haploinsufficiency is associated with a very subtle DNA hypo-
methylation phenotype in hematopoietic cells, myeloid lineage
expansion over time, and the development of myeloid malig-
nancies after a very long latent period (∼18 mo), during which
cooperating mutations are acquired (16). All of these observa-
tions suggest that Dnmt3a haploinsufficiency and deficiency
create an epigenetic state that somehow facilitates the acquisi-
tion of cooperating mutations and transformation.
In this report, we asked whether restoration of DNMT3A
activity in hematopoietic cells with Dnmt3a deficiency could
“repair” the hypomethylated regions. To address this issue, we
designed a genetic proof-of-principal experiment where we re-
stored DNMT3A expression in the bone marrow cells of adult
mice engrafted with Dnmt3a-deficient hematopoietic cells. The
restoration of DNMT3A activity resulted in the accurate reme-
thylation of nearly all hypomethylated DMRs over a period of
6 mo. DMRs were remethylated in an orderly fashion; fast vs. slow
remethylating DMRs had unique features that suggest that they
may be associated with important biological activities. Reme-
thylation of the Dnmt3a-deficient genome partially reversed
dysregulated gene expression and myeloid skewing, suggesting
that this epigenetic state is at least partially reversible.
Results
Dnmt3a-Deficient Bone Marrow Samples Have a Focal, Canonical
Hypomethylation Phenotype. Mice that lack Dnmt3a at birth are
runted and die within ∼3 wk (25), but the hematopoietic cells of
these mice can be transplanted into secondary recipients for
longitudinal analysis of hematopoietic function. We therefore
used a secondary transplantation model for all experimental and
control mice in this study, which involved collection of bone
marrow cells from 2.5-wk-old littermate-matched Dnmt3a
knockout and WT control mice (referred to as Dnmt3a−/− or
Dnmt3a+/+ henceforth) and transplantation into lethally irradi-
ated C57BL/6 secondary recipients. The donor mice expressed
CD45.2, and the recipients were chosen to express CD45.1,
which allowed us to track and sort the donor cell populations for
all downstream analyses. We used three pairs of matched 6-wk-
posttransplant Dnmt3a−/− and Dnmt3a+/+ mice to define DMRs
for all subsequent experiments.
Whole-genome bisulfite sequencing was used for all DNA
methylation studies. On average, these datasets covered 20.6
million out of 21.0 million (98%) of the individual CpGs in the
mouse genome, with excellent reproducibility between biological
replicates (Pearson’s r > 0.8 for each of three samples in either
Dnmt3a+/+ or Dnmt3a−/−).
The mean CpG methylation values were significantly lower in
all annotated regions of the genome in the Dnmt3a−/− bone
marrow samples; CGI, CGI shores, CGI shelves, and promoters
had the largest differences (Fig. 1A). The distribution of meth-
ylation values across the genome for each sample showed highly
similar methylation patterns among individual mice (Fig. 1B).
We next identified all DMRs between the Dnmt3a+/+ and
Dnmt3a−/− samples, as previously described (14). DMRs were
required to have >10 CpGs, a mean methylation difference
between the two groups of >0.2, and a false discovery rate
(FDR) of <0.05. Contiguous DMRs within 50 base pairs (bp) of
each other were merged (the average sizes and CpG content of
DMRs are described below). Using these criteria, we identified
8,480 DMRs in the Dnmt3a−/− samples; 8,466 out of 8,480 DMRs
(99.83%) were hypomethylated in the Dnmt3a−/− bone marrow
samples (Fig. 1 C and D and Dataset S1). In total, these DMRs
encompassed ∼7.63 megabases (Mb) of DNA, representing about
2.5% of the genome.
The focal and canonical nature of the 8,480 DMRs is revealed
in heatmaps that display the average methylation value of each
DMR as a unique data point. Methylation patterns of the
transplanted Dnmt3a+/+ and Dnmt3a−/− samples are nearly
identical to that of primary bone marrow samples harvested from
2-wk-old germline null Dnmt3a mice (Fig. 1E) (16, 25) (referred
to as Dnmt3a+/+2wk and Dnmt3a−/−2wk); since the methylation
patterns are preserved in Dnmt3a−/− bone marrow cells engrafted
into WT mice, the methylation phenotype must represent a cell-
autonomous property of bone marrow stem/progenitor cells.
An example of a DMR in Dnmt3a−/− vs. Dnmt3a−/−2wk bone
marrow samples is shown in Fig. 1F (highlighted by gray box) in
the 5′ flanking region of the Ggt1 gene. The DMR pattern is
remarkably consistent among all mice with the same genotype
(i.e., it is canonical), a finding that was recapitulated for virtually
all DMRs examined.
Many CpGs in the DMRs of Dnmt3a−/− samples are almost
completely unmethylated (beta values less than 0.05) in total
bone marrow samples, which consist of distinct populations of
cells representing different hematopoietic lineages (i.e., myeloid,
erythroid, lymphoid, etc.). This suggested that the normal
Dnmt3a-dependent methylation “marks” may be added in stem/
progenitor cells, and then maintained in all lineages (presumably
by Dnmt1, and also Dnmt3a) (26). Because of improvements in
Whole Genome Bisulfite Sequencing (WGBS) library prepara-
tion techniques (that use as little as 50 ng of input DNA), we
were able to test this hypothesis with flow cytometry-purified
populations of relatively rare progenitor cells. We performed a
progenitor-specific WGBS analysis using Dnmt3a+/+ vs.
Dnmt3a−/− sorted bone marrow cells from an enriched stem/pro-
genitor cell population (KLS), committed myeloid progeni-
tors (CMP and granulocyte−monocyte progenitor [GMP]),
megakaryocyte-erythroid progenitors (MEP), and mature lineage
compartments (CD11b+/Gr-1+ myeloid cells, and B220+ B cells).
We passively plotted the methylation data from these compartments
using the 8,480 DMRs defined above for whole bone marrow
(Fig. 2 A and B) and observed a nearly identical methyl-
ation pattern in the flow-purified cells from the Dnmt3a+/+ and
Dnmt3a−/− cells in all six compartments, which strongly suggests
that the normal Dnmt3a-dependent methylation marks were added
in stem/progenitor cells, and then maintained in all lineages as they
differentiate. Although each of these compartments has a unique
methylation signature pertinent to its specialized functions (27),
the compartments also have common locations where Dnmt3a
acts. Fig. 2C displays an exemplary DMR in the 5′ flanking region
of theGgt1 gene (gray box, the same as that shown in Fig. 1F) with
a nearly identical methylation phenotype in all compartments
tested.
Doxycycline-Regulated Expression of the DNMT3A Transgene in
Hematopoietic Cells. To determine whether expression of DNMT3A
could remethylate the DMRs associated with Dnmt3a loss in he-
matopoietic cells, we developed a transgenic mouse capable of
expressing WT human DNMT3A at near-physiologic levels in
mouse hematopoietic stem/progenitor cells (HSPCs). A full-length
human complementary DNA (cDNA) encoding the WT
DNMT3A1 isoform was cloned into a mammalian expression vector
directly downstream from a tetracycline responsive element (SI
Appendix, Fig. S1A), and a transgenic mouse line was propagated






































from a founder mouse with a random single-copy insertion on
chromosome 1 at position 192,986,250 (based on mm9 coordi-
nates), just downstream from the Fam71a gene. As expected, this
transgene is expressed in a doxycycline dose-dependent fashion in
mice that also express the rtTA coactivator (ubiquitously expressed
via insertion in the Rosa26 locus). The rtTA and DNMT3A trans-
genic lines were intercrossed with mice heterozygous for the same
Dnmt3a mutation described above, a deletion of parts of exons 18
and 19 described originally by Okano et al. (25). With appropriate
backcrosses, we created Dnmt3a−/− x rtTA x DNMT3A transgenic
mice, which are subsequently referred to as “Dnmt3a null-3A
addback mice.” Since these mice die with runting at about 3 wk
of age (as expected) (2, 3), we harvested the bone marrow cells of
these mice (Ly5.2) at 14 to 18 d of age, and transplanted them into
lethally irradiated C57BL/6 recipients (Ly5.1). Engraftment was
assessed 4 to 6 wk later by defining the size of the Ly5.2 population
in the peripheral blood; engraftment rates of >80% were routinely
detected (see below). Within transplanted cohorts, half of the mice
were placed on doxycycline chow (10,000 parts per million [ppm], a
dose shown to induce near-physiologic levels of DNMT3A in mouse
HSPCs; see below), and half received normal chow without doxy-
cycline. Whole bone marrow was harvested from two independent
sets of mice at 1, 2, and 4 wk (two each with Dox and two without
Dox) and one mouse each at 8, 18, and 24 wk (one with Dox and
one without Dox), and these samples were subjected to WGBS,
as described below.
To examine the expression of the tetracycline-regulated DNMT3A
transgene, we evaluated total RNA-sequencing (RNA-seq) data
from the bone marrow cells of mice fed for 2, 8, or 24 wk with or
without Dox chow. Dnmt3a gene expression was defined by
mapping all reads from the direct location of the Dnmt3a deletion
in exons 18 and 19 (in counts per million); humanDNMT3A exons
18 and 19 are 95% identical to the mouse (228 of 240 bp are
identical), so human DNMT3A messenger RNA reads map to the
same sites in the mouse genome. These data defined the loss of
reads from these exons in Dnmt3a−/− bone marrow cells, and also
defined the numbers of reads found in transplanted Dnmt3a+/+
marrow cells, which were significantly different (P = 0.05). In
Dnmt3a null-3A addback mice fed with normal chow, expression
levels remain at levels near zero. In mice fed with Dox chow,
DNMT3A expression was restored to levels that were similar to
that of WT transplanted mice (SI Appendix, Fig. S1B). Immu-
noblotting of whole bone marrow lysates after feeding Dox chow
for 1 wk or 4 wk revealed that transgenic DNMT3A protein
levels were similar to that of endogenous Dnmt3a in the bone
marrow cells of 2-wk-old WT mice (SI Appendix, Fig. S1C; this
polyclonal rabbit antibody cross-reacts with mouse and human
DNMT3A). Dnmt3a was undetectable in 6-wk-posttransplant
Dnmt3a+/+ marrow, suggesting that Dnmt3a is normally down-
regulated in hematopoietic cells after 2 wk of age.
We then defined endogenous and transgenic DNMT3A






































































Dnmt3a+/+ Dnmt3a−/−P *<.05, **< .01, ***<.001





































































Fig. 1. DNA methylation phenotypes of Dnmt3a+/+
and Dnmt3a−/− bone marrow cells. (A) Mean CpG
methylation levels from whole-genome bisulfite se-
quencing of bone marrow cells derived from
Dnmt3a+/+ (n = 3) and Dnmt3a−/− mice (n = 3), har-
vested 6 wk after transplantation into lethally irra-
diated recipients. Mean values for all CpGs and
annotated regions of the genome are shown. Hy-
pothesis testing was performed via two-tailed, pair-
wise t tests, with Bonferroni correction for multiple
testing within each genomic region; *P < 0.05; **P <
0.01; ***P < 0.001. Small but statistically significant
differences are consistently observed in the methyl-
ation status of Dnmt3a+/+ and Dnmt3a−/− bone
marrow cells across the genome. (B) Density plot of
methylation values from all CpGs for each bone
marrow sample shown in A. (C) Density plot of CpG
methylation values from 8,480 DMRs defined by
comparing the Dnmt3a+/+ (n = 3) and Dnmt3a−/− (n =
3) samples. (D) Aggregate (mean) methylation of
8,480 DMRs for each bone marrow sample. DMRs
were scaled to a uniform length and are shown with
the adjacent 5 kb of flanking sequence. The bar
represents the span of the scaled DMR regions (see
Methods). (E) Heatmap showing mean methylation
values for the 8,480 DMRs as defined above. Values
for the same DMRs were plotted passively for
Dnmt3a+/+2wk and Dnmt3a−/−2wk samples (processed
directly from 2-wk-old mice, and not transplanted).
(F) Primary methylation values for each CpG (shown
as a bar from 0 to 100%methylated for each sample)
near a Dnmt3a−/− hypomethylated DMR in the 5′
flanking region of the Ggt1 gene. This region was
identified as a DMR by comparing methylation val-
ues for Dnmt3a+/+ vs. Dnmt3a−/− or Dnmt3a−/−2wk
samples (P = 3.20E-08 and 2.10E-15 byMann−Whitney
U test with Bonferroni correction).
















































lineage-defined cells, using a quantitative flow-based assay, using
fixed, permeabilized cells and a rabbit monoclonal antibody that cross-
reacts between human and mouse DNMT3A/Dnmt3a. The mean
fluorescent intensity of the DNMT3A-specific signal was used
to estimate protein abundance. We detected an induction of
DNMT3A protein in all populations analyzed in DNMT3A add-
back mice, relative to the untreated Dnmt3a null-3A addback
mice controls (SI Appendix, Fig. S1D and Dataset S2). After 4 wk
of Dox feeding, the levels of induced DNMT3A expression were
similar to that of endogenous Dnmt3a in the progenitor and LSK-
SLAMpopulations (SLAM, 1.1-fold; LSK, 0.8-fold; CMP, 0.7-fold;
GMP, 1.6-fold; MEP, 1.0-fold). However, mature, lineage-
restricted cells (myeloid, erythroid, and B cells) expressed more
DNMT3A protein than was detected inWT cells of the same lineage
(myeloid, 5.4-fold; erythroid, 4.2-fold; and B cells, 4.8-fold; SI Ap-
pendix, Fig. S1D and Dataset S2). This pattern of transgene in-
duction closely parallels expression of the rtTA transactivator in
the Rosa26 locus, as previously described (28). These data are also
consistent with previous observations showing that the endogenous
expression of human DNMT3A is less in the myeloid, erythroid,
and lymphoid lineages compared to the LSK, progenitor, and LSK-
SLAM populations (SI Appendix, Fig. S1D) (5).
Remethylation of DMRs as a Function of Time and Genomic Context.
Our WGBS data resulted in coverage of >98% of the CpGs in
the mouse reference genome, with a mean of 10× to 12× cov-
erage for each sample. We calculated the mean DMR methyl-
ation values for the 8,480 DMRs in the Dnmt3a null-3A addback
bone marrow cells derived from mice fed normal vs. Dox chow
(10,000 ppm) for 1 to 24 wk. Importantly, none of the
Dnmt3a−/− mice used in these studies had any evidence of a
hematopoietic malignancy at harvest (e.g., abnormal CBCs or
enlarged spleens). The mean methylation values of the DMRs
steadily increased as a function of time on Dox chow. The addback
of DNMT3A begins to restore methylation at DMRs starting at
week 1, with further increases at weeks 2 and 4, and near-complete
remethylation after 24 wk of feeding Dox chow (Fig. 3A). Overall,
these results suggest that DNMT3A expression restores meth-
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Fig. 2. Canonical DMRs identified in whole bone
marrow (WBM) cells are conserved in multiple he-
matopoietic progenitor compartments and lineages.
(A) Heatmap showing mean methylation values for
the 8,480 DMRs from the unfractionated WBM cells
of Dnmt3a+/+ (n = 3) and Dnmt3a−/− mice (n = 3).
Values for the same DMRs were plotted passively for
the KLS, GMP, CMP, and MEP compartments, and for
mature flow-sorted populations consisting of Gr1+
cells (mature myeloid) and B220+ cells (predominantly
B cells); “+/+” and “−/−” refer to the Dnmt3a genotype
of each population. (B) Aggregate (mean) methylation
at 8,480 DMRs as described in A: myeloid progenitor
compartments: KLS, GMP, CMP, and MEP and mature
populations, neutrophils, and B cells are plotted pas-
sively for the same loci. DMRs were scaled to a uniform
length and are shown with the adjacent 5 kb of
flanking sequence. The bar represents the span of
the scaled DMR regions. (C) Primary methylation
values for each CpG (shown as a bar from 0 to 100%
methylated for each sample) near a Dnmt3a−/− DMR
in the 5′ flanking region of the Ggt1 gene (gray box;
see Fig. 1F). This region is significantly hypomethylated
in total bone marrow samples, and all other purified
cellular compartments (P = 3.30E-45 and P < 2.2e-16 by
Mann−Whitney U test with Bonferroni correction).






































Regardless, nearly all DMRs were eventually remethylated (Fig.
3 B–D).
We evaluated donor cell chimerism in all mice at harvest to
determine whether there was selection against the donor Dnmt3a−/−
cells (Ly5.2) with Dox feeding, and reciprocal enrichment of Dnmt3a+/+
recipient cells (Ly5.1); if this occurred, the “remethylation response”
would simply be due to replacement of the Dnmt3a−/− cells with
WT cells. However, the bone marrows of all transplanted mice,
with or without Dox chow, remained >80% donor-derived
(Dnmt3a−/−, Ly5.2+) at all time points (SI Appendix, Fig. S2).
Therefore, the observed remethylation response is not caused by
a slow replacement of the Dnmt3a-deficient cells by WT cells.
To determine whether persistent expression of the DNMT3A
transgene caused DNA hypermethylation, we evaluated DNA
methylation patterns across the entire genome in WT mice
containing the rtTA transgene, with or without the WT DNMT3A
transgene. These mice were fed Dox chow (10,000 ppm) for 1.5 y,
and then bone marrow was harvested for WGBS (SI Appendix,
Fig. S3A). No annotated region of the genome was significantly
hypermethylated in mice that expressed the DNMT3A transgene
for 1.5 y. Further, we evaluated DMRs and low methylation re-
gions (LMRs) for evidence of hypermethylation with long-term
DNMT3A expression (SI Appendix, Fig. S3B). We identified
23,294 LMRs (which have very low levels of CpG methylation in
both WT and Dnmt3a−/−samples) using the hmr program in the
“methpipe” package, using the same parameters described in
Spencer et al. (14). LMRs were defined as hypomethylated in all
samples (regardless of Dnmt3a genotype) with coverage-
weighted mean methylation values of <0.2 encompassing >5
CpGs. Long-term expression of theDNMT3A transgene did not lead
to significant hypermethylation of LMRs, where Dnmt3a clearly
does not act (SI Appendix, Fig. S3 B, Right). Finally, we evaluated
the extent of remethylation in all annotated regions of the genome
with Dnmt3a null-3A addback mice (SI Appendix, Fig. S3C). As
expected, the methylation values from mice eating normal chow
were essentially equivalent to Dnmt3a−/− mice. The mice that ate
Dox chow (10,000 ppm) had gradual restoration of methylation at
all annotated regions, which were statistically equivalent to that of
WT cells at week 24 of Dox feeding. These data suggest that
remethylation caused by expression of the DNMT3A transgene in
this model system does not result in nonspecific hypermethylation
of DNA.
Based on the finding that most remethylation takes place by
week 4, we decided to further evaluate the characteristics of fast,
intermediate, and slow remethylating DMRs at that time point
(Fig. 3B and Dataset S1). We divided the DMRs into quartiles
(fastest remethylation in quartile 1, slowest in quartile 4) based
on the distribution of differences between Dnmt3a−/− bone
marrow and Dnmt3a null-3A addback bone marrow cells from
mice fed Dox chow for 4 wk. Mean methylation differences in
the DMRs were highest in quartile 1 (Q1) and lowest in quartile
4 (Q4; SI Appendix, Fig. S4 B–E). By definition, the DMRs of Q1
remethylated rapidly, and were virtually all restored to WT val-
ues by week 8. In contrast, a small number of Q4 DMRs did not
completely remethylate to WT values even by week 24. The
specific patterns and rates of remethylation at individual DMRs
in individual mice were consistent and reproducible, suggesting
that remethylation is an ordered, locus-dependent process that
follows a set of specific rules. However, since the bone marrow is
a heterogeneous mixture of cells, we also considered the possi-
bility that different rates of remethylation might exist in different
subsets of cells (e.g., progenitors, mature myeloid, or mature B
cells), due to different rates of cell division, different levels of
transgene expression, and/or other factors. We therefore com-
pared WGBS data from purified Kit+Lin− cells, CD11b+/
Gr1+ cells, or B220+ cells from a pair of mice engrafted with
Dnmt3a null-3a addback bone marrow and fed normal chow vs.
Dox chow, for 2 wk (SI Appendix, Fig. S5). As expected, DMRs
in the purified populations fed normal chow (i.e., no DNMT3A
expression) were essentially identical to that of Dnmt3a−/− total
bone marrow DMRs. In bone marrow from the mouse fed with
Dox chow for 2 wk, remethylation was apparent in all compart-
ments, but was greatest in the mature myeloid cells, suggesting
that this rapidly dividing population (with higher levels of DNMT3A
transgene expression than progenitors; SI Appendix, Fig. S1D)
is remethylated more quickly than the B cell population. Re-
methylation of the Kit+/Lin− progenitor population was similar to
that of total bone marrow cells at 2 wk. These data suggest that
mature myeloid cells do contribute disproportionately to the early
remethylation phenotype, but that the general pattern of reme-
thylation is similar in progenitor and lineage-restricted cells.
To determine whether these fast vs. slow remethylating DMRs
were associated with specific genomic properties, we performed
a series of studies to better define their characteristics. First, we
quantified the numbers of DMRs within each quartile that were
annotated to specific regions of the genome. CGI, shores, and
intergenic regions tended to be enriched for DMRs associated
with the slow remethylating quartiles (SI Appendix, Fig. S6A).
The faster remethylating DMRs of Q1 were enriched in gene
bodies, and had the lowest number of DMRs mapping to CGI,
shores, and intergenic regions. The physical width of DMRs was
smallest in Q1 and greatest in Q4 (870.1 ± 560.7 bp vs. 925.3 ±
819.3 bp; P < 0.05) (SI Appendix, Fig. S6B). The CpG content of
DMRs was the lowest in Q1 and highest in Q4 (18.9 ± 10.4
CpGs/DMR vs. 24.3 ± 18.2 CpGs/DMR; P < 0.001) (SI Ap-
pendix, Fig. S6C). Finally, using RNA-seq data from the single-
cell sequencing samples described below, we found that the
mean levels of gene expression were significantly higher in Q1 >
Q2 > Q3 > Q4 in both the Dnmt3a+/+ and Dnmt3a−/− samples,
when considering all genes in all cells (SI Appendix, Fig. S7); this
suggests that genes associated with fast remethylating DMRs are
more transcriptionally active.
We annotated pathways associated with genes within 5 kb of
the nearest DMR using Protein Analysis Through Evolutionary
Relationships (http://pantherdb.org/) (29–32). We compared the
gene lists using Mus musculus as the reference organism, and
identified biological processes associated with each quartile (SI
Appendix, Fig. S8). Genes near faster remethylating DMRs were
significantly enriched for pathways involving hematopoiesis, cell
death, development and differentiation, signaling, and tran-
scription, whereas genes associated with more slowly remethy-
lating DMRs were mainly enriched for cell death pathways.
Using the HOMER algorithm (33), we searched for sequence
motifs that were enriched in the DMRs of Q1 vs. Q4, but none
were identified as statistically significant.
Gene Expression Patterns Associated with Dnmt3a-Deficient Hematopoietic
Cells. Bulk RNA-seq studies of Dnmt3a+/+ vs. Dnmt3a−/− total
bone marrow cells revealed only 106 differentially expressed genes
(DEGs), including Dnmt3a itself, as expected (Dataset S3). Some
of these genes were on the X and Y chromosomes, since the sexes
of the Dnmt3a+/+ vs. Dnmt3a−/− samples were different. Although
the small number of changes in gene expression are consistent
with previously published studies (14, 16, 18), we suspected that
gene expression changes in subpopulations of cells were being
masked with RNA-seq from a pool of all bone marrow cells. We
therefore performed single-cell RNA-seq (scRNA-seq) on total
bone marrow cells from mice that had been transplanted 12 wk
earlier with Dnmt3a+/+ vs. Dnmt3a−/− donors, using the 10× Ge-
nomics Chromium platform, as previously described (16, 34). We
evaluated cryopreserved bone marrow cells with or without sorting
for viability from the same donor mice, and the results were es-
sentially equivalent; we therefore pooled the data for the analyses
shown in Fig. 4. After applying standard approaches for data fil-
tration using Partek Flow software, we inferred the lineage of each
cell using a k-nearest neighbor algorithm trained on the Haemopedia
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Fig. 3. Restoration of DNMT3A expression is associated with remethylation of Dnmt3a−/−-dependent DMRs in bone marrow cells. (A) Global mean meth-
ylation of the 8,480 DMRs over time (weeks). Red dots represent Dnmt3a−/− as baseline values, followed by values for samples from mice fed with Dox (i.e.,
DNMT3A reexpression) for the designated time in weeks. There are two independent datasets for weeks 1, 2, and 4, and one dataset each for weeks 8, 18, and
24. By week 24, DNMT3A reexpression causes near-complete remethylation of these DMRs compared to the methylation levels in Dnmt3a+/+ bone marrow
(dark blue dots). (B) Heatmap of mean methylation values from the 8,480 DMRs. The columns are grouped by Dnmt3a−/−, Dnmt3a−/− x WT DNMT3A x rtTA
without and with Dox, and Dnmt3a+/+. Low methylation levels in the DMRs frommarrow derived from the Dnmt3a−/− x WT DNMT3A x rtTA mice without Dox
remain unchanged over time. Time-dependent restoration of methylation across all DMRs is observed in Dnmt3a−/− x WT DNMT3A x rtTA/with Dox, where the
24-wk time point shows near-WT levels of methylation. Quartiles of 2,120 DMRs representing fast (Q1), intermediate (Q2 and Q3), and slow (Q4) reme-
thylating regions are shown on the right. (C and D) Aggregate (mean) methylation at 8,480 DMRs from Dnmt3a+/+ and Dnmt3a−/− samples (n = 3, each). DMRs
from Dnmt3a−/− x WT DNMT3A x rtTA bone marrow (C) without Dox and (D) with Dox were plotted passively for the same 8,480 DMRs. In both C and D, DMRs
have been scaled to a uniform length, and are shown with the adjacent 5 kb of flanking sequence. Bars represent the span of the scaled DMR regions. (E and
F) Aggregate (mean) methylation at 23,294 LMRs. Dnmt3a−/− x WT DNMT3A x rtTA (E) without Dox and (F) with Dox were plotted passively for the same
LMRs. In both E and F, LMRs have been scaled to a uniform length and are shown with the adjacent 5 kb of flanking sequence. Bars represent the span of the
scaled LMR regions.






































Database (35) (Fig. 4A). Although all lineages were present in
both genotypes, the Dnmt3a−/− marrow samples had a significant
reduction in the proportions of B cells, CD8+ T cells, dendritic
cells, and macrophages, and a significant enrichment in mature
myeloid cells (polymorphonuclear cells [PMNs]; Fig. 4B).
Identification of DEGs for whole bone marrow, PMNs, and
macrophage populations are shown using volcano plot projections
in Fig. 4C, and expression data are shown in Datasets S4–S6. In all
three populations, the vast majority of genes were not differen-
tially expressed. Using data from all cells (whole bone marrow),
172 genes were significantly up-regulated in Dnmt3a-deficient
cells (fold change ≥ 2.0, FDR ≤ 0.01), and 716 genes were sig-
nificantly down-regulated (fold change ≤ −2.0, FDR ≤ 0.01). In
an analysis restricted to PMNs, 59 genes were significantly up-
regulated, and 329 genes were down-regulated; in macrophages,
340 genes were significantly up-regulated, and 110 genes were
down-regulated. TheGgt1 gene, which has a canonical DMR in its
5′ flanking region (Figs. 1 and 2), is expressed at significantly
higher levels in Dnmt3a−/− PMNs, but is not dysregulated in
macrophages (Ggt1 labels in Fig. 4C); since PMNs represent the
most abundant population in the bone marrow, this change can
also be detected in the whole bone marrow data (Dataset S4) and
bulk RNA-seq data (Dataset S3). Of the 67 DEGs up-regulated in
Dnmt3a−/− bone marrow cells identified by bulk RNA-seq, 8 were
concordantly and significantly up-regulated in the scRNA-seq
whole bone marrow sample data; of the 39 down-regulated DEGs,
5 were concordantly down-regulated using the scRNA-seq data.
However, most of the genes that were differentially expressed in
small populations of cells were not detected in the bulk RNA-seq
data (Dataset S3), or by using scRNA-seq data pooled from all
bone marrow cells (Dataset S4).
To evaluate the consistency of differential gene expression
among cells assigned to the same lineage, we created heatmaps
showing the expression values for all DEGs for lineage-defined
cells from each genotype (Fig. 4D). In both PMNs and macro-
phages, most cells from each lineage have a canonical expression
phenotype for each DEG, revealing that these are consistent
effects across many similar cells, and not driven by small outlier
populations.
Finally, we evaluated the relationship between DMRs and
gene expression for each of these populations (Fig. 4E). We
determined the average expression values for each of the 2,513
genes located within 5 kb of the 8,480 DMRs defined in Fig. 1.
The difference in methylation values between Dnmt3a+/+ vs.
Dnmt3a−/− cells is shown on the x axes; nearly all DMRs are
hypomethylated in Dnmt3a−/− bone marrow cells. The differ-
ences between the average expression values for each of the
DMR-associated genes are represented on the y axes. For each
population, the majority of DMR-associated genes had slightly
lower expression levels in Dnmt3a−/− cells. Overall, differences in
expression were not significantly correlated with methylation
differences, demonstrating the complex and difficult-to-predict
relationships between methylation patterns and gene expression
in hematopoietic cells (7, 13, 14, 16, 17, 36).
Differentially Expressed Genes in HSPCs. The scRNA-seq data de-
scribed above clearly demonstrate a shift in the proportions of
mature myeloid and macrophage-like cells in Dnmt3a-deficient
bone marrow, suggesting that an alteration in the expression of
one or more lineage-defining factors may occur inDnmt3a-deficient
progenitors. Because progenitor cells are rare, we performed
scRNA-seq on progenitor-enriched (Kit+/Lineage depleted) bone
marrow cells derived from mice transplanted with Dnmt3a+/+ vs.
Dnmt3a−/− bone marrow cells (Fig. 5). Representations of the cel-
lular composition of these samples are shown in t-distributed sto-
chastic neighbor embedding (t-SNE) plots in Fig. 5A, and the
fractions of defined populations are quantified in Fig. 5B. Most
populations are equivalent in the two samples, but the GMP
population was significantly smaller in the Dnmt3a−/− sample.
DEGs defined for all of the cells in this dataset are displayed in a
volcano plot (Fig. 5C) and an expression heatmap (Fig. 5D and
Dataset S7). A total of 280 genes were significantly up-regulated in
Dnmt3a−/− progenitors, and 190 genes were down-regulated; most
genes exhibited a trend toward down-regulation that was not sig-
nificant (note the downward shift in nonsignificant genes between a
fold change of −2 and +2). Gene ontology pathways enriched in the
down-regulated gene set were most highly enriched for processes
associated with neutrophil aggregation, inflammatory responses to
antigenic stimuli, and leukocyte migration involved in inflammatory
responses, among others (SI Appendix, Fig. S9). We specifically
evaluated the expression of a set of well-characterized genes known
to be important for myeloid vs. monocyte/macrophage lineage de-
termination (i.e., Spi1, Gfi1, IL6ra, Csf1r, Cebpa, and Irf8; expres-
sion levels for each are identified on the volcano plot in Fig. 5C)
(37–52). Irf8 was expressed at significantly reduced levels in the
Dnmt3a-deficient progenitors, but the other genes were not dysre-
gulated. The expression of Irf8 in individual cells (using the same
t-SNE projection as used in Fig. 5A) is shown in Fig. 5E. Ifr8 is
expressed in fewer cells in the Dnmt3a−/− sample, and the expres-
sion level per cell is also significantly reduced (Fig. 5F). Since Irf8 is
known to drive progenitor cells toward the monocyte/macrophage
lineage at the expense of myeloid cells, its down-regulation in
Dnmt3a−/− progenitors would be expected to increase myeloid dif-
ferentiation at the expense of the monocyte/macrophage lineage.
Addback of DNMT3A Partially Corrects Myeloid Skewing and Gene
Expression Changes. To determine whether reactivation of
DNMT3A expression altered hematopoietic cell populations and/
or gene expression over time, we transplanted Dnmt3a−/− bone
marrow cells into four secondary recipients, documented en-
graftment 4 wk later, and then placed two mice on Dox chow
(10,000 ppm) and two mice on normal chow; mice with and
without Dox feeding were harvested 8 and 22 wk later, and bone
marrow cells were subjected to scRNA-seq. We identified the
transcriptional outputs of all cells, and defined clusters with
lineage annotation (Fig. 6A); quantification of all cell types in
the 8- and 22-wk addback samples are shown in Fig. 6B. Al-
though skewing toward the myeloid lineage was apparent in the
sample pair harvested after 8 wk, there were minimal changes in
the proportions of all cell types with Dox feeding. In the sample
pair harvested at 22 wk, a dramatic skewing of the sample toward
myeloid cells was apparent in the Dnmt3a−/− mouse that was fed
normal chow. However, with Dox feeding, a partial restoration
of other lineages was apparent, and the proportion of myeloid
cells in the bone marrow was significantly reduced.
We evaluated global trends in gene expression associated with
these two pairs of addback samples. Fig. 6C displays the global
pattern of expression of genes located within 5 kb of a DMR,
with genes expressed at higher levels in Dnmt3a−/− bone marrow
cells on top and those at lower levels on the bottom. When the
expression values of the same genes were “passively” plotted for
the 8-wk addback samples (Fig. 6 C, Middle), no trend toward
correction of gene expression was apparent. However, with 22 wk
of Dox feeding, a reduction in the expression of the up-regulated
genes was apparent, and, conversely, there was a tendency to-
ward increased expression of the down-regulated genes. For
genes that were not associated with DMRs (Fig. 6D), there was
no evidence of correction at 8 wk of Dox feeding, but, at 22 wk,
the down-regulated genes displayed a tendency toward increased
expression, while expression of regulated genes was not altered.
Because Irf8 was expressed at lower levels in the progenitors of
Dnmt3a− /− mice, we evaluated its expression in the 8- and
22-wk addback sample pairs (Fig. 6D). Mean expression
levels of Irf8 in GMPs increased significantly after 8 and 22
wk of Dox feeding. We also evaluated DNA methylation
within the body of the Irf8 gene (Fig. 6E), and found that
















































CpGs within the gene body were canonically hypomethylated
in Dnmt3a− /− bone marrow cells. These gene body CpGs
were remethylated as a function of time, with nearly com-
plete correction at week 24. Since gene body methylation is
often associated with high levels of gene expression (53–56),
the loss of methylation of the Irf8 gene body may contribute
to its decreased expression, while its restoration corresponds
to increased expression.
We also evaluated the expression and remethylation patterns
of cells of Ggt1, which has a canonical DMR in its 5′ flanking
region (Figs. 1 and 2), and which is expressed at higher levels in
Dnmt3a−/− PMNs (Fig. 6). We evaluated the expression of Ggt1
in individual cells from Dnmt3a+/+ and Dnmt3a−/− bone marrow
samples (SI Appendix, Fig. S10A): Its expression is essentially
restricted to PMNs; the fraction of PMNs expressing Ggt1 in-
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Fig. 4. Dnmt3a−/− bone marrow cells have population-restricted DEGs, and a myeloid lineage bias. (A) The t-SNE projections of scRNA-seq data from whole
bone marrow cells derived from mice transplanted with Dnmt3a+/+ (n = 2; Left) or Dnmt3a−/− donors (n = 2; Right), and showing known hematopoietic
populations based on Haemopedia gene expression profiling (35). (B) Population fractions associated with the scRNA-seq data shown in A; * indicates FDR <
0.05 via Fisher’s exact test with multiple hypothesis correction. (C) Volcano plots showing DEGs in whole bone marrow, PMNs, and macrophage populations
(MACs) from Dnmt3a−/− mice (FDR ≤ 0.01, FC ≤ −2, ≥ 2). (D) Heatmaps of normalized (Z-score) expression values for 388 DEGs identified in PMNs (59 up-
regulated and 329 down-regulated) and 450 DEGs identified in macrophages (340 up-regulated and 110 down-regulated). Numbers of cells represented in
each grouping are shown at the bottom of each heatmap. (E) Methylation difference of each DMR associated with a gene within 5 kb (x axis), plotted against
the difference in expression values between Dnmt3a+/+ and Dnmt3a−/− cells (y axis). Inset numbers indicate the fraction of genes in each quadrant. Nearly all
DMRs associated with genes are hypomethylated, and the majority of these genes are expressed at lower levels in Dnmt3a−/− cells.






































level of Ggt1 RNA per expressing cell increases from 2.91 in
WT cells to 17.6 in Dnmt3a−/− cells, (6.05-fold, P < 0.01; SI
Appendix, Fig. S10B). Data from the 8-wk addback sample pair
revealed a 3.3-fold reduction of Ggt1+ cells with Dox feed-
ing (6.03% vs. 1.81%), and a significant reduction in mean
Ggt1 expression per expressing cell (SI Appendix, Fig. S10B).
The 22-wk sample from Dnmt3a-deficient mice (“no Dox”)
revealed a striking increase in Ggt1-expressing PMNs
(12.96%) that was reduced with Dox feeding (0.92%); like-
wise, the average expression level of Ggt1 in the 22-wk no Dox
sample was even more elevated than in earlier samples, and
was reduced to near-baseline levels in mice that were fed Dox
chow (SI Appendix, Fig. S10B). Finally, the hypomethylated
DMR located ∼5 kb upstream from Ggt1 was progressively
remethylated over time with Dox chow feeding, exhibiting
near-WT levels of methylation at week 24 (SI Appendix,
Fig. S10C).
Discussion
In this report, we describe an experimental system that allowed
us to determine the accuracy and rate of DNA remethylation
in hematopoietic cells that were constitutively deficient for
Dnmt3a. The bone marrow cells of these mice had a focal,































































































































p=4.85 p < 2.2-9 -16
Fig. 5. Dnmt3a−/− progenitors express reduced Irf8. (A) The t-SNE projections of scRNA-seq data from Dnmt3a+/+ (Left) and Dnmt3a−/− (Right) lineage-
negative (i.e., depleted for cells expressing B220, CD19, CD11b, Ter119, and/or CD71), c-KIT−positive cells with known populations assigned according to Haemopedia
gene expression profiling. (B) Population distributions assigned using the scRNA-seq data shown in A; * indicates FDR < 0.05 via Fisher’s exact test and multiple
hypothesis correction. (C) Volcano plot showing DEGs in lineage-negative, c-KIT−positive cells from Dnmt3a−/−mice (FDR ≤ 0.01, fold change ≤ −2, ≥ 2). The values for
several transcription factors associated with myelomonocytic lineage determination are shown. (D) Heatmap of normalized (Z-score) expression values for 470 DEGs
(280 up-regulated, and 190 down-regulated) identified in lineage-negative, c-KIT−positive cells defined by the comparison of Dnmt3a+/+ vs. Dnmt3a−/−cells. Numbers
of cells represented in each grouping are shown at the right of the heatmap. (E) Cells colored red according to levels of Irf8 expression in Dnmt3a+/+ (Left) and
Dnmt3a−/− (Right) lineage-negative, c-KIT−positive cells. (F) Mean expression levels (Left) and fractions of cells positive for Irf8 relative to total cells (Right).
















































changed after transplantation into secondary recipients. Using
a “tet-on” system to express WT human DNMT3A1 in these
bone marrow cells, we found that DNA remethylation was
detectable within a week, and nearly complete within 6 mo. The
pattern of remethylation was highly ordered and consistent
from mouse to mouse, suggesting that DMRs possess unique,
locus-dependent features that help to define the rate at which
they are remethylated. Long-term, enforced expression of transgenic
DNMT3A did not result in hypermethylation of regions where
Dnmt3a does not normally act, and did not cause global hyper-
methylation of the genome. Dnmt3a-deficient hematopoietic
cell genomes can therefore be accurately remethylated in a
genetically defined system. Using scRNA-seq approaches, we
were able to define population-restricted DEGs in Dnmt3a-
deficient hematopoietic cells, and show that DNMT3A addback
caused a general trend toward correction of gene expression over
time. This response was also associated with the gradual cor-
rection of the myeloid-enriched phenotype of Dnmt3a-deficient
bone marrow cells.
The expression of WT human DNMT3A in Dnmt3a-
deficient bone marrow cells resulted in rapid changes in
DNA methylation in most DMRs, but some remethylated
more quickly than others. The speed of remethylation of in-
dividual DMRs was ordered and stereotypical, suggesting that
DMRs have unique, context-dependent properties that affect
their ability to be recognized by or acted on by DNMT3A.
These data strongly suggest that Dnmt3a must interact dif-
ferently with specific regions of the genome, and these regions
are defined by signals that do not require any prior exposure to
Dnmt3a during development. The nature of these signals is
currently unclear: we were not able to identify any sequence
motifs within DMRs that distinguished fast vs. slow remethylating
regions, nor were there any geographically restricted regions of
the genome where remethylation occurred more rapidly. How-
ever, the recent identification of H3K36me2 and H3K36me3 as
recruiters of DNMT3A to specific regions of the genome may
offer a clue regarding how these regions may be targeted for
methylation by DNMT3A (57).
The phenotypes associated with Dnmt3a deficiency—and
remethylation—developed over extended periods of time, for
unclear reasons. Even though this model system is based on
constitutive Dnmt3a deficiency, the myeloid skewing phenotype
was only minimally apparent at 2 wk of age, and became more
pronounced over time; this suggests that acquired genetic and/or
epigenetic events are very important for the shift toward myeloid
enrichment. Many of the downstream effects of remethylation
(i.e., correction of gene expression and myeloid skewing) oc-
curred long after remethylation was detected. Although the
reasons for this are not yet clear, we suggest that remethylation
of late precursors and more mature cells—the most prevalent
cells in the marrow—may have only small effects on gene expres-
sion or cell fate determination, since these cells may be irrevers-
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Fig. 6. Restoring DNMT3A expression partially corrects myeloid skewing
and dysregulated gene expression in Dnmt3a−/− bone marrow cells. (A) The
t-SNE projections of scRNA-seq data of whole bone marrow from recipient
mice transplanted with Dnmt3a null-3A addback bone marrow and fed
normal chow (no Dox), or 10,000 ppm Dox chow (with Dox) for the indicated
times. Known populations are annotated according to Haemopedia gene
expression profiling. (B) Population percentages identified using the scRNA-
seq data from 8 wk (Top) or 22 wk (Bottom) of Dox chow feeding; * indicates
FDR < 0.05 via Fisher’s exact test with multiple hypothesis correction. (C)
Expression changes in DEGs within 5 kb of a DMR, defined by comparing
Dnmt3a+/+ vs. Dnmt3a−/− cells. Plots are split into up-regulated genes (Top)
or down-regulated genes (Bottom). Left shows the log fold change differ-
ence of each gene in Dnmt3a+/+ vs. Dnmt3a−/− cells. Middle and Right pas-
sively plot the expression values for the same sets of DEGs, displaying the
effects of feeding Dox for 8 or 22 wk. Yellow lines indicate the median ex-
pression value for each set of genes. (D) Identical to C, but displaying DEGs not
associated with a DMR. (E) Fraction of GMPs positive for Irf8 expression in
Dmnt3a+/+ (blue) vs. Dnmt3a−/− (red) bone marrow cells, identified by scRNA-
seq. The expression of Irf8 in GMPs is significantly increased after 8 or 22 wk of
feeding Dox chow (red vs. blue bars). (F) Remethylation of differentially
methylated CpGs in the Irf8 gene body with Dox feeding (orange line). No
remethylation was detected in mice fed with normal chow (blue line).






































status. If the key changes in methylation must occur in HSPCs, the
consequences may occur more slowly, since these cells divide only
infrequently, and since it can take weeks to months for phenotypes
to appear in their progeny. Clearly, additional studies will be re-
quired to better understand the kinetics of the observed phenotypes
in this system.
Previous gene expression studies of Dnmt3a haploinsufficient
or deficient mouse bone marrow cells, and studies of human
AML samples initiated by DNMT3A mutations, have failed to
yield highly reproducible expression signatures (13, 14, 16). In-
deed, our bulk sequencing studies of Dnmt3a−/− bone marrow
cells revealed very few DEGs. However, scRNA-seq ofDnmt3a−/−
bone marrow samples revealed hundreds of highly reproducible
DEGs that were usually cell lineage- and/or developmental stage-
specific. The relationships of these expression changes with DMRs
were locus- and DMR-specific, and did not conform to a set of
rules that could be applied globally. With DNMT3A addback, a
general trend toward a correction of the gene expression patterns
was detected, but the relationship of corrected expression and
local remethylation was not clear for most genes. These findings
demonstrate the continuing difficulty of establishing rules linking
patterns of local DNA methylation and gene expression, a decades-
old conundrum (58, 59); clearly, many factors besides DNA
methylation are important for determining gene expression levels
at any given locus.
The scRNA-seq data revealed hundreds of genes that are
dysregulated in specific populations of Dnmt3a-deficient cells,
but the importance of any individual gene for the observed he-
matopoietic phenotypes is not yet clear. We evaluated two genes
(one up-regulated and one down-regulated) in greater detail to
illustrate some of the features associated with potentially rele-
vant candidates. Ggt1 encodes gamma-glutamyltransferase 1, an
enzyme that catalyzes reduced glutathione to cysteine and gly-
cine, delivering cysteine to the cell to facilitate the synthesis of
glutathione, a major intracellular antioxidant that protects cells
from oxidant stresses (60). Although its expression has not pre-
viously been described in either normal or malignant myeloid
cells, it is up-regulated in the myeloid cells of Dnmt3a-deficient
mice; a canonical hypomethylated DMR located several kilo-
bases upstream of Ggt1 is remethylated with DNMT3A addback,
and the gene is eventually down-regulated. The location of this
DMR suggests that it may act as a proximal regulatory element or
enhancer for this gene when unmethylated. However, no func-
tional studies of this element have yet been described, so the
importance of this DMR for Ggt1 up-regulation in myeloid cells
will require functional validation. In contrast, Irf8 is a transcrip-
tion factor that is down-regulated in Dnmt3a-deficient progenitor
cells, where its gene body is hypomethylated; expression of this
gene is known to induce progenitors to commit to the monocyte/
macrophage lineage. Down-regulation of Irf8 is associated with
the induction of neutrophilic maturation (38, 50–52, 61), which is
observed in Dnmt3a haploinsufficient and deficient hematopoietic
cells. DNMT3A addback was associated with Irf8 gene body
remethylation, restoration of its expression, and the partial cor-
rection of time-dependent myeloid skewing; although the mech-
anisms responsible are not yet clear, the relationship of gene body
methylation with gene expression is well described (53–56). Al-
though extensive functional studies will be needed to fully un-
derstand the roles of individual genes for the phenotypes of
Dnmt3a-deficient hematopoietic cells, these two genes provide
examples of how candidate genes can be selected for functional
validation.
The experimental system described here has caveats that may
have influenced some of our observations. For example, we
expressed a human DNMT3A transgene that was regulated in-
directly by the Rosa26 locus, not the Dnmt3a locus. Although the
transgene was expressed at near-physiologic levels in HSPCs, it
was relatively overexpressed in committed progenitors and more
mature cells of all lineages; this may explain why remethylation
occurred more quickly in mature cells of the myeloid lineage.
Further, endogenous Dnmt3a is clearly down-regulated in nor-
mal bone marrow cells a few weeks after birth, but the transgene
is persistently expressed in Dox-fed animals throughout life. Fi-
nally, we did not evaluate addback phenotypes in Dnmt3a hap-
loinsufficient mice (which are more like human patients with
heterozygous loss-of-function mutations), because these mice
have very subtle phenotypes (16) that would have been very
difficult to evaluate with this model system. Although these ex-
perimental details may have influenced some phenotypes, we
suggest that the fundamental conclusion of the study is still valid:
enforced expression of DNMT3A in Dnmt3a-deficient bone
marrow cells causes ordered and accurate DNA remethylation as
a function of time.
In summary, these data suggest that CpGs that would normally
be methylated by Dnmt3a remain “recognizable” in the genomes
of cells that have never previously expressed the enzyme, and
that some of the effects of Dnmt3a deficiency can be corrected
by genetically reexpressing the WT protein. Although this ap-
proach would be impractical in humans with loss-of-function or
dominant-negative DNMT3A mutations, it may be possible to
engineer small molecules that can increase DNMT3A activity by
altering its ability to homodimerize or homotetramerize, or that
inactivate mutant forms of the enzyme. Although much addi-
tional work will be required to determine whether this will be
possible, the current study does suggest that the genome retains
signals that can direct DNMT3A to its proper sites of action,
restore normal DNA methylation at these sites, and partially
correct the phenotypes associated with Dnmt3a deficiency. This
suggests that patients with ARCH or AML caused by mutations
in DNMT3A could derive therapeutic benefit from an approach
that restores the full activity of this enzyme.
Methods
Generation and Propagation of Mice. A construct containing a tetracycline-
inducible, WT human DNMT3A1 cDNA (SI Appendix, Fig. S1A) was intro-
duced into the C57Bl6/J genome, and founders were crossed with R26-M2rtTA
mice in the B6 background. A complete description can be found in Results
and SI Appendix, Supplementary Methods.
Immunoblotting/Flow Cytometry. Bone marrow cells from mouse femurs
were utilized for flow cytometry applications. Antibodies against well-
characterized cell surface receptors were used for identification and sort-
ing of defined populations. Details can be found in SI Appendix, Supplementary
Methods.
Bisulfite Sequencing. Bisulfite sequencing was performed, as described in Cole
et al. (16), aligned with biscuit, and DMRs were called using metilene (62),
and smoothed/combined using the bsseq package (63). Full details and pa-
rameters are in SI Appendix, Supplementary Methods.
Total RNA Sequencing, Processing, and Analysis. The Illumina TruSeq Stranded
kit was used to produce bulk RNA-seq data, which used TopHat (64) and
Stringtie (65) for alignment and expression quantification. DEGs were called
using edgeR (66, 67). Additional details can be found in SI Appendix,
Supplementary Methods.
Single-Cell RNA Sequencing, Processing, and Analysis. Single-cell RNA libraries
were created using the 10× Genomics Chromium Single Cell 5′ Kit, aligned
with CellRanger, and assigned to lineages using cellMatch. The characteris-
tics of each sample are summarized in Dataset S8. Additional filtering and
defining of DEGs were done using Partek Flow software. Full details and
parameters used are in SI Appendix, Supplementary Methods.
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